Hamsa-1 (TL-118) / Tiltan Pharma - LARVOL DELTA

Results of a Phase I study of TL118 in patients with advanced solid tumors with NTRK gene fusions (CSCO 2024) - No abstract available

Clinical • Metastases • P1 data • Oncology • Solid Tumor • NTRK

[VIRTUAL] Large-scale study of NTRK fusions in Chinese solid tumors and using next generation sequencing: A multicenter study (AACR-II 2020) - "TRK inhibitors such as LOXO-101, entrectinib, X396, AB-106, TL118 had remarkable and durable antitumor activities in patients (pts) with TRK fusion-positive cancers, regardless of age or tumor type. NTRK fusions are a rare molecular subtype in Chinese solid tumors. The NTRK gene fusions more commonly occurred in NSCLC (0.3%), CRC (0.4%) and BC (0.2%), and may occur without other targetable alterations such as EGFR, ALK, ROS1. The clinical evidence for responsiveness of NTRK fusions driven solid tumors provides an opportunity to personalize treatments and improve clinical outcomes for patients (pts)."

Biomarker • Clinical • Next-Generation Sequencing • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Thoracic Cancer • ALK • CALR • EGFR • ESRP1 • ETV6 • LMNA • NTRK • NTRK1 • NTRK2 • NTRK3 • ROS1 • SQSTM1 • TPM3